Allegria Therapeutics – Mastering Mast Cells
to redefine the treatment of allergic and inflammatory diseases.
Allegria aims to bring joy to patients.
The name Allegria is derived from the element allegro which means ‘happy, lively, merry’.
It refers to our commitment to restore quality of life for people suffering from allergy and inflammatory diseases associated with mast cell dysfunction.
Science
Allergic diseases are on the rise
Approximately 1 in 3 people1,2 in developed countries are affected by:
- Allergies
- Intolerances
- Asthma
- Skin problems
These pathologies are driven by uncontrolled mast cell activity
Mast cells are long-lived, tissue-resident immune cells whose repeated pathological activation and degranulation are central drivers of allergic and inflammatory diseases. Depending on the triggering allergen and affected organs, mast cell-mediated disorders manifest across a broad clinical spectrum, ranging from mild conditions such as conjunctivitis and rhinitis to asthma, urticaria, atopic dermatitis, angioedema, food allergies and, in severe cases, life-threatening anaphylaxis.3
Allegria provides a direct & selective mast cell targeting platform for optimal efficacy & safety
Allegria targets mast cells
directly
to maximize activity
[as opposed to indirectly through activators and mediators]
Allegria targets mast cells
selectively
to ensure best possible safety
[we sidestep targeting ubiquitous biology]
Allegria’s lead program
Validated target rooted in mast cell biology
First-in-class and best-in-disease potential
Small molecule allowing for oral dosing
Allegria is currently advancing its lead program toward preclinical candidate selection, supporting the nomination of its first development candidate.
Team
Allegria is backed by an experienced team of drug developers, mast cell biology experts, and disease-leading clinicians.
Maria van Dongen
PhD
CEO & Co-founder, Director
Patrick Sieber
PhD
VP Operations
Johanna Kammann
PhD
Scientific Writer & Project Manager
Philipp Starkl
PhD
Scientific Advisor & Collaborator
Tamás Schweighoffer
MD, PhD
Advisor
Daniel Robinson
PhD
Computational Chemistry
José Brea
PhD
Small Molecule Screening
Harry Chobanian
PhD
Medicinal Chemistry/ DMPK
Beatriz Goyenechea
PhD
Antibody Discovery & Development
Dan Becker
MD, JD
Intellectual Property
Scientific Advisory Board
David Evans
PhD
DMPK & PD Translational Sciences
Martin Metz
MD, PhD
Dermatology & Allergology
Mark Scarupa
MD
Allergology & Immunology
Philipp Starkl
PhD
Immunology & Allergology
Board of Directors
Sara Núñez-García
PhD, MBA
Chairperson
Peter Sejer Andersen
PhD
Board Member
Sascha Oliver Bucher
MBA, CEFA
Board Member
Maria van Dongen
PhD
Board Member
Stine Kjellev
PhD
Board Observer
Xijin Xu
PhD
Board Observer
Investors
Co-founding Investor
Lichtsteiner Foundation | Allegria Therapeutics Testimonial Film
Maria van Dongen and Patrick Sieber explain why mast cells are central to many allergic and inflammatory diseases, and how Allegria aims to provide better treatment options for those patients.
News
€1.3M Funding For MastCURe’s Innovative Mast Cell-Directed Therapies
Read more.
Allegria Therapeutics Secures USD 5.1 Million Seed Extension Financing
Read more.
Allegria Therapeutics Announces Seed Financing of USD 3.5 Million
Read more.
Contact Us
Leave your message and we will get back to you.
By submitting this form, you agree to the processing of your data so that we can respond to your inquiry. For more information, please refer to our Privacy Policy.
1 L Bottoms-McClain, A Giri and AE Ng; National Center for Health Statistics (U.S.): Diagnosed Allergic Conditions in Adults: United States, 2024
2 The European Academy of Allergy and Clinical Immunology (EAACI) Advocacy Manifesto, 2015
3 P Kolkhir, D Elieh-Ali-Komi, M Metz, et al. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol, 2022